Most independent pharmacies belong to a pharmacy services administrative organization, and most owners could not say precisely what their PSAO is responsible for. That vagueness is not laziness. The arrangement genuinely covers a lot of ground, and the boundaries are in documents nobody reads at renewal.
Worth drawing the line clearly, because the things on the far side of it do not get done by default.
What a PSAO is
A PSAO contracts with PBMs on behalf of a group of independent and small chain pharmacies. Instead of each store separately credentialing, negotiating and signing with every network, the PSAO does it once and its members participate through that relationship.
The scale argument is straightforward. The FTC’s July 2024 interim staff report found that three PBMs manage roughly 79 percent of prescription claims for around 270 million people. A single store negotiating individually against that concentration is not a negotiation.
The market itself is concentrated and largely wholesaler-linked. Per Milliman’s PSAO landscape research and Drug Channels’ market analysis, McKesson’s Health Mart Atlas is the largest, with more than 6,100 pharmacy locations, Cencora owns Elevate Provider Network, and Cardinal Health operates PSAO services of its own. AlignRx was formed from the 2021 merger of Arete Pharmacy Network, owned by American Associated Pharmacies, with PPOk, and now operates several distinct networks.
What it genuinely does
Network access. One credentialing and contracting relationship instead of dozens. For a single-store pharmacy this is not a convenience, it is the difference between being in networks and not.
Contract execution. The PSAO signs on your behalf, usually under an agency agreement or power of attorney, and manages amendments and network change notices as they arrive.
Credentialing and re-credentialing. Ongoing, deadline-driven, and genuinely tedious at volume.
Central pay, in some models. The PBM pays the PSAO, which remits to you, consolidating many payment streams into fewer. Whether this is an advantage depends entirely on the remittance detail you get back, which is discussed below.
MAC appeal submission. Most PSAOs will file appeals on your behalf through the routes they maintain with each PBM.
Audit coordination. Notification, document routing, and in many cases direct support in responding.
Communication. Rate changes, network terminations, new preferred network offers and the deadlines attached to them.
That is a real service, and for most independents the alternative is not a better deal, it is no deal.
What it structurally does not do
It does not negotiate a bespoke rate for your store. Network offers arrive at network level and are largely take it or leave it. A PSAO improves your access, not your individual pricing power. Frier Levitt has made the point directly in the context of effective rate contracts: PSAOs negotiating on behalf of pharmacies do not necessarily have comparable bargaining power to the PBMs across the table, and the member pharmacies bear the financial consequences of terms they had no direct input into.
It does not guarantee reimbursement above your acquisition cost. No PSAO contract promises this and none could.
It is not a buying group. Purchasing economics come from your wholesaler agreement, your generic compliance rate and any GPO arrangement. Some organisations sit alongside a buying group under common ownership, which makes the two easy to conflate. They are different contracts with different economics.
It does not monitor your claim-level margin. This is the largest gap and the least understood. PSAO reporting is generally aggregate. Appeals are typically reactive to what you flag. If you do not identify the below-cost claim and raise it, in most arrangements nothing happens, and several PBM appeal windows run in business days from the initial claim rather than from the date the remittance arrives.
It does not carry your compliance or audit risk. Coordination is not indemnity. The licence, the records, the copay collection documentation and the inventory reconciliation are yours, and in an audit they are what is examined.
It does not necessarily let you take one contract and decline another. Bundled network participation is common. Whether you can opt out of an individual agreement varies by PSAO and by network, and it is a specific question with a specific answer in your agreement.
It does not shield you from network-level reconciliation. Where a generic effective rate is measured across the PSAO’s book, your recoupment reflects the aggregate performance of hundreds of pharmacies you have never met.
Ownership is a fair question to ask
Most of the large PSAOs are owned by or affiliated with pharmaceutical wholesalers. This is a structural fact about the market rather than an accusation, and there are sound commercial reasons for it: the wholesaler already has the relationship, the credit exposure and the data.
It does mean the entity negotiating your network access and the entity selling you inventory may sit under one corporate parent. That is worth understanding rather than worrying about. Ask directly how it works, what is separated and what is not, and how conflicts are handled. A well-run organisation will answer plainly.
What to ask at renewal
Which contracts am I currently in, and may I see the reimbursement terms for each. Can I decline an individual contract without leaving the whole network. Who holds the power of attorney and what is its exact scope. How are MAC appeals submitted, what is the turnaround, and will you report outcomes back to me claim by claim. Central pay or direct pay, and what claim-level detail comes with the remittance. What happens to my claim data, who else sees it, and in what form. What are the fees, and are they flat, per claim, or a percentage. What is the termination notice period. In an audit, what exactly do you do and what remains mine. What reporting do I receive, at what granularity, and how quickly.
The remittance detail question deserves particular attention under a central pay model. If what arrives is a net figure without per-claim ingredient cost, dispensing fee, patient pay amount and Basis of Reimbursement Determination, you cannot run contract-to-claim reconciliation at all, and the underpayment analysis stops before it starts.
The division of labour that works
The arrangement that functions well looks like this. The PSAO owns access and administration: contracting, credentialing, appeal submission, audit coordination, network communication. You own the economics: what each claim actually paid against what the drug actually cost, which contracts are underperforming, and which claims are worth appealing this week.
That split works because the PSAO’s appeal engine is only as good as the flags it receives, and nobody outside your four walls knows your net acquisition cost. Attergo Compliance tracks the credentialing dates, contract obligations and network deadlines that arrive through the PSAO, and Attergo Audit keeps the claim, invoice and documentation trail together for when a request lands. Neither replaces a PSAO, and neither should. They cover the half of the relationship that was always yours.